Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Prostatype Genomics

0,52 SEK

-7,83 %

Mindre end 1K følgere

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Sammenligne
-7,83 %
-8,48 %
-9,12 %
-57,37 %
-91,39 %
-88,55 %
-99,45 %
-99,89 %
-99,86 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Læs mere
Markedsværdi
30,66 mio. SEK
Aktieomsætning
153,58 t SEK
Omsætning
200 t
EBIT %
-20.425 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
12.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse25.11.2025, 13.30

Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Prostatype Genomics
Pressemeddelelse19.11.2025, 07.06

BioStock: Video from Prostatype Genomic's presentation at BioStock Life Science Summit 2025

Prostatype Genomics
Selskabsmeddelelse11.11.2025, 14.45

Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics

Prostatype Genomics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse24.9.2025, 20.45

New shares from exercise of warrants of series TO5 registered

Prostatype Genomics
Selskabsmeddelelse18.9.2025, 17.00

Prostatype Genomics AB receives SEK 11.5 million in connection with warrants of series TO5

Prostatype Genomics
Selskabsmeddelelse12.9.2025, 07.05

The last day of trading in Prostatype Genomics AB’s warrants of series TO5 is on Monday

Prostatype Genomics
Selskabsmeddelelse3.9.2025, 18.55

Prostatype Genomics AB enters into pre-subscription and top-down underwriting commitments corresponding to 37.2 percent in ongoing warrant exercise

Prostatype Genomics
Selskabsmeddelelse3.9.2025, 06.45

The exercise period for Prostatype Genomics AB’s warrants of series TO5 commences today

Prostatype Genomics
Selskabsmeddelelse2.9.2025, 06.45

Prostatype Genomics AB announces fixed exercise price for warrants of series TO5

Prostatype Genomics
Pressemeddelelse28.8.2025, 14.00

Update regarding Prostatype Genomics’ application to Medicare concerning reimbursement for Prostatype® in USA

Prostatype Genomics
Selskabsmeddelelse26.8.2025, 06.30

Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype® to insurance companies in the USA

Prostatype Genomics
Selskabsmeddelelse7.8.2025, 18.15

Prostatype Genomics AB changes Certified Adviser to Tapper Partners AB

Prostatype Genomics
Selskabsmeddelelse23.7.2025, 10.10

Prostatype Genomics publishes its interim report for the first half of 2025

Prostatype Genomics
Pressemeddelelse22.7.2025, 12.05

Positive results for Prostatype® confirmed in published Spanish multicentre study

Prostatype Genomics
Selskabsmeddelelse23.6.2025, 10.15

Prostatype Genomics' Newsletter: Initiated clinical use at several U.S. top-ranked hospitals and urology clinics

Prostatype Genomics
Selskabsmeddelelse19.6.2025, 19.15

Prostatype Genomics AB announces last day of trading in BTU and first day of trading in warrants of series TO5

Prostatype Genomics
Selskabsmeddelelse18.6.2025, 11.30

Prostatype Genomics AB carries out directed issue of units to underwriters in recently completed rights issue

Prostatype Genomics
Selskabsmeddelelse5.6.2025, 20.20

Prostatype Genomics AB’s rights issue of units fully subscribed

Prostatype Genomics
Selskabsmeddelelse3.6.2025, 07.00

Strong results for Prostatype® in published Taiwan study – creating opportunities for commercial expansion in Asia

Prostatype Genomics
Pressemeddelelse2.6.2025, 06.45

Prostatype Genomics engages Healthcare Capital Mergers as U.S. transaction advisor

Prostatype Genomics
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.